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diagnosis and an acceptable incremental cost per diagnosis when
compared to typical costs of syncope hospitalizations in Sweden.
ILRs are a cost-effective means of achieving a diagnosis in
patients suffering from recurrent unexplained syncope. Further
work could incorporate HRQoL beneﬁts because of reduced
time-to-diagnosis and faster access to treatment. Faster access to
care may also demonstrate cost-savings by preventing death, falls
and fractures while patients remain without treatment.
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OBJECTIVES: To combine clinical results of Endevor® clinical
trials and the associated costs of its use in patients with de novo
lesions of the coronary arteries. METHODS: An economic
model of ENDEAVOR® was constructed based on a retrospective
cost-effectiveness analysis. The basic data of the model were
taken from the literature and expert opinion, and reﬂect the
clinical and economic consequences of the management of new
coronary lesions within the context of the Spanish National
Health System. Expert opinion was obtained from semi
structured interviews and panel consensus from interventional
cardiologists working in seven different Spanish Regions (Auto-
nomias). Only local costs were included, and a discount of 3.5%
was applied to the future costs and outcomes. Probabilistic Sen-
sitivity Analysis) PSA, was performed to evaluate robustness of
our results. RESULTS: Endeavor® had higher total costs than the
bare metal stent and the costs per Target Lesion Revasculariza-
tion avoided with Endeavor® was €6851 (per year) and €10,831
(5 years). In terms of costs per Major Adverse Cardiac Event
avoided with Endeavor®, the results were €7003, €8362 and
€11,322, respectively at year 1, 2 and 5, and the costs per QALY
gained was €132,877, €34,229 and €10,505 at year 1, 2, and 5
years, respectively.The budgetary impact of the progressive intro-
duction of Endeavor® would be practically null, representing
0.4% on the total costs of percutaneous coronary interventions
at 5 years. CONCLUSIONS: The use of the Endeavor® stent
compared to the Bare metal stent and Coronary artery bypass
graft represents an efﬁcient use of resources in coronary artery
disease patients, with cost-effectiveness results below the thresh-
old of efﬁciency deﬁned in Spain. Further real life prospective
data related QoL and health care resources utilization may
improve model accuracy.
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OBJECTIVES: To describe treatment patterns of Glycoprotein
Inhibitors (GPI) and clopidogrel in patients presenting with acute
coronary syndrome (ACS). METHODS: A prospective observa-
tional registry in 3 countries, recruited ACS patients undergoing
percutaneous coronary intervention (PCI), January–August
2007, capturing practice patterns, resource use and quality of
life. RESULTS: A total of 1525 ACS pts (Spain-538, UK-504,
France-483), mean age 62 (SD 12), mean wt 80 kg (SD 15), 22%
female were recruited. Index diagnosis: unstable angina (UA)
and non ST-elevation myocardial infarction (NSTEMI) 62%;
ST-elevation myocardial infarction (STEMI) 38%. Ninety-ﬁve
percent of patients were treated with clopidogrel, whereas 34%
of patients received GPIs (abciximab-21%; eptiﬁbatide-3%);
tiroﬁban-11%) before, during or after PCI. The overall use of
GPIs was balanced between the three countries (Spain-35%,
UK-33%, France-36%). Abciximab was the most frequently
used GPI and was administered mainly in the catherisation labo-
ratory (76%) at the time of PCI. The small molecule GPIs were
more commonly administered before PCI (eptiﬁbatide-55%;
tiroﬁban-78%) and to a lesser extent in the catherisation labo-
ratory (eptiﬁbatide-42%; tiroﬁban-19%). Of the patients who
received abciximab, 60% were STEMI, 26% NSTEMI, and 13%
UA. Administration of abciximab before PCI was more frequent
in STEMI patients (23%) than in UA (5%) and NSTEMI patients
(9%). CONCLUSIONS: Of the 34% of ACS patients receiving a
GPI, abciximab was the most frequently used and was predomi-
nantly administered in the catherisation laboratory, whereas the
other GPIs were more often initiated before. This ﬁts with the
NSTE-ACS guidelines recommendation of the European Society
of Cardiology (ESC). In the STEMI abciximab cohort, an
increase in pre-treatment could be observed.
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OBJECTIVES: Despite statins are accepted as standard for reduc-
ing CHD risk by ~30% via their inﬂuence on LDL-Cholesterol
level, they do not prevent the majority of clinical events like MI,
coronary death or stroke. In addition to other modiﬁable risk
factors like hypertension or diabetes, persistent dyslipidemia,
expressed as LDL-C above target and/or low HDL-Cholesterol
(HDL-C) or high triglycerides (TG), is likely to play a major
causative role in the residual risk of cardiovascular (cv) events
in statin treated patient. As little recent information is available
on the prevalence of persistent dyslipidemia in statin treated out-
patients, this cross sectional survey will diminish this gap.
METHODS: As part of a paneuropean study, 1255 patients in
Germany pretreated with a statin for at least 3 months (45.4%
with diabetes, 14.2% smoker) were included in the period of April
and May 2008. Their cv risk proﬁle was documented and modi-
ﬁable risk factors were compared with current guidelines.
RESULTS: A total of 39.9% of patients had LDL-C levels below
100 mg/ml (median 106.7 mg/dl), 71.4% had HDL-C levels
above 40 (males)/50 (females) mg/dl (median 51 mg/dl), 66.5%
withTGbelow150 mg/dl (median 140,0 mg/dl). A total of 19.1%
of patients had all 3 lipid values within the mentioned ranges.
A total of 39.8% had blood pressure (RR) above 140/90 mmHg,
12.8% of patients had RR values below 140/90 mmHg and lipid
levels within the desired ranges. BMI was 28.1 kg/m2. CONCLU-
SIONS: Since 2000, comprehensive lipid management and treat-
ment of modiﬁable risk factors in Germany has improved over
time but remains still suboptimal and deserves further attention,
which is similar to a prior report from German hospitals.
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